北京若生智能科技有限公司
Drug Database
AN

anti-tetanus immunoglobulin (Tetglob)

✓ Approved

Bharat Serums and Vaccines Limited · 治疗药物

什么是 anti-tetanus immunoglobulin？

anti-tetanus immunoglobulin 是一种治疗药物，由Bharat Serums and Vaccines Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Tetglob
公司Bharat Serums and Vaccines Limited
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Bharat Serums and Vaccines Limited

治疗适应症

anti-tetanus immunoglobulin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedTranslational pediatrics2026-09-11

Traditional Chinese medicine combined with conventional Western medicine for chronic cough following respiratory infection in children: a systematic review and meta-analysis.

Cui Shengtao S, Xie Xiaofei X, Yang Jingjing J, Xiao Yao Y et al.

Chronic cough following respiratory infection in children is often refractory to conventional therapies. However, the current clinical evidence regarding the efficacy of traditional Chinese medicine (TCM) remains inconclusive and lacks systematic synthesis, leaving clinicians without clear guidance. This study systematically evaluated the efficacy and safety of TCM for chronic cough following respiratory infection in children to support clinical decision-making. A systematic search was conducted in the Cochrane Library, PubMed, Embase, Web of Science, Wiley Online Library, China National Knowledge Infrastructure (CNKI), and Wanfang databases. Randomized controlled trials (RCTs) of TCM for chronic cough following respiratory infection in children were included. Meta-analyses were performed using RevMan 5.4 and Stata 16.0. A total of 23 RCTs involving 2,126 children were included. Meta-analysis demonstrated that, compared with conventional Western medical treatment alone, TCM combined with conventional treatment significantly improved the overall clinical effectiveness rate [risk ratio (RR) =1.19, 95% confidence interval (CI) (1.15, 1.24), P<0.001], shortened the time to cough resolution [mean difference (MD) =-3.19, 95% CI (-4.42, -1.97), P<0.001] and the time to disappearance of pulmonary rales [MD =-2.00, 95% CI (-2.47, -1.54), P<0.001], and significantly reduced cough symptom scores [MD =-1.32, 95% CI (-1.69, -0.95), P<0.001]. For secondary outcomes, combined TCM therapy significantly reduced TCM syndrome scores, improved immune function indicators [immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG)], and decreased levels of inflammatory biomarkers [C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-4 (MCP-4)]. No statistically significant difference was observed between groups in the incidence of adverse events. TCM used as an adjunct to conventional Western medical treatment may provide additional benefits in improving clinical outcomes and alleviating symptoms in children with post-infectious chronic cough. However, due to limitations in study quality and heterogeneity, further high-quality, well-designed studies are warranted to strengthen the evidence base.

PMID 42724356
阅读全文 →
PubMedThe British journal of dermatology2026-09-11

Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.

Joly Pascal P, Murrell Dedee F DF, Aoyama Yumi Y, Caux Frédéric F et al.

Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are rare, chronic, potentially life-threatening, immunoglobulin (Ig)G-mediated, autoimmune skin and/or mucosal blistering diseases. Efgartigimod, a human IgG1 antibody Fc fragment, blocks the neonatal Fc receptor, decreasing IgG recycling and reducing both healthy and pathogenic IgG autoantibody levels. To investigate the efficacy, safety and impact of subcutaneous efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in conjunction with prednisone in the treatment of pemphigus. Adult participants with newly diagnosed or relapsing moderate-to-severe pemphigus were recruited in this phase III, prospective, multicentre, randomised, double-blinded, placebo-controlled study (NCT04598451). Participants were randomised (2 : 1) to weekly subcutaneous efgartigimod PH20 or placebo. Subcutaneous efgartigimod PH20 2000 mg was administered on days 1 and 8, followed by 1000 mg weekly until complete remission on minimal prednisone therapy (CRmin) (≤ 10 mg daily). All participants received concomitant prednisone starting at 0.5 mg kg-1 daily. The primary outcome was the proportion of participants with PV who achieved CRmin by week 30, while receiving minimal prednisone, for ≥ 8 weeks. Pharmacodynamics and safety were also assessed. Overall, 222 participants (PV: n = 190; PF: n = 32) were randomised (subcutaneous efgartigimod PH20: n = 147; placebo: n = 75). The proportions of participants with PV achieving CRmin within 30 weeks were comparable between the subcutaneous efgartigimod PH20 and placebo groups, with no statistically significant difference observed [44/124 (35.5%) vs. 20/66 (30.3%); P = 0.60; odds ratio 1.19 (95% confidence interval 0.60-2.41)]. Total prednisone consumption over time was comparable between groups. Subcutaneous efgartigimod PH20 resulted in rapid reductions from baseline in total IgG and anti--desmoglein-1 and anti-desmoglein-3 autoantibody levels, but these did not translate to improvements in Pemphigus Disease Area Index scores. The rates of adverse events (AEs) in the subcutaneous efgartigimod PH20 and placebo groups were 89.1% (n = 131/147) and 76.0% (n = 57/75), respectively; most were mild to moderate [serious AEs: 12.2% (n = 18/147) and 13.3% (n = 10/75), respectively]. No deaths occurred. Subcutaneous efgartigimod PH20 in combination with systemic corticosteroids did not demonstrate clinical benefit over systemic corticosteroids alone in patients with moderate-to-severe pemphigus at 30 weeks, but it was well tolerated in this patient population.

PMID 42723554
阅读全文 →
PubMedVector borne and zoonotic diseases (Larchmont, N.Y.)2026-09-11

Bartonella and Rickettsia Seroreactivity among an Antenatal Cohort in 2020-2022 Central North Carolina: Prevalence and Birth Outcomes.

Abernathy Haley A HA, Zychowski Diana D, Mokashi Neha N, Giandomenico Dana D et al.

Spotted fever group Rickettsia (SFGR) and Bartonella henselaeare emerging pathogens with overlapping clinical presentation. Though they are transmitted by different vectors, both possess biologically plausible mechanisms for long-term disruption of vascular signaling and blood vessel function. The goal of this study was to estimate the seroprevalence of B. henselae and SFGR antibodies among pregnant women attending antenatal care clinics in Orange, Chatham, Alamance, Durham, Person, and Caswell Counties of North Carolina. This study also aimed to investigate potential associations between seroreactivity and adverse maternal or perinatal outcomes. Remnant sera were collected from pregnant women undergoing routine antenatal care at UNC Health facilities between March 1, 2020, and June 30, 2022. From the available samples, we generated a representative cohort. Specimens underwent testing for SFGR and B. henselae-specific immunoglobulin G. Adjusted and unadjusted prevalence ratios of adverse outcomes were estimated and stratified by exposure status. A total of 568 samples were tested. Antibody reactivity against SFGR was present in 9.2% (95% confidence interval [CI]: 6.8 - 11.5%) of the study population, while anti-B. henselae antibody reactivity was detected in 4.1% (95% CI: 2.4 - 5.7%). Adjusted prevalence ratios of adverse perinatal outcomes in seroreactive and nonreactive individuals ranged from 0.89 to 1.22. Our findings indicate that nearly 1-in-10 (9.2%) pregnant women in central NC have serological evidence of exposure to SFGR, while 1-in-25 (4.1%) have evidence of exposure to Bartonella. Though we did not find evidence of an association between seroreactivity and adverse outcomes, only a small number of individuals with adverse outcomes were seroreactive to either pathogen. Thus, larger samples will be needed to adequately measure the degree of association, if any exists, between perinatal outcomes and seroreactivity.

PMID 42723418
阅读全文 →
PubMedTranslational cancer research2026-09-11

STC1 is associated with tumor progression and suppressive niches in laryngeal squamous cell carcinoma.

Chen Xiaoxue X, Li Wenjing W, Liu Yiyao Y, Zhang Lei L et al.

Laryngeal squamous cell carcinoma (LSCC) exhibits high recurrence and therapy resistance. We aimed to investigate the undefined role of Stanniocalcin-1 (STC1) in LSCC pathogenesis. The single-cell RNA sequencing (RNA-seq) data and the clinical information of LSCC patients were acquired from the public database. Prognostic differences and diagnostic efficiency of STC1 were assessed. The gene correlation was investigated by Spearman method. Enrichment analysis was performed using clusterProfiler, and immune infiltration was assessed with CIBERSORT. Finally, we analyzed the distribution of specific STC1 expression in cell types using single-cell RNA sequencing (scRNA-seq) analysis, and cell communication for ligand-receptor interactions between STC1+ cells and T cell subsets. The upregulated STC1 was linked to tumor metastasis and disease stage in LSCC. It correlated with genes involved in extracellular matrix (ECM) remodeling, epithelial-mesenchymal transition (EMT), phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance. High STC1 expression was linked to an immunosuppressive microenvironment, with increased M0 macrophages and reduced CD8+ T cells, and was positively correlated with the immune checkpoints [programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), T cell immunoglobulin and ITIM domain (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3)]. Single-cell analysis localized STC1 to epithelial cells, with STC1+ epithelial cells showing enriched endoplasmic reticulum (ER) stress, inflammatory signaling, and EMT during carcinogenesis. Cell-cell communication analysis revealed that STC1+ epithelial cells engage T cell subsets through more ligand-receptor pairs in the transforming growth factor-beta (TGF-β) and B- and T-lymphocyte attenuator (BTLA) pathways compared to STC1- epithelial cells. These findings indicate STC1 is strongly correlated with signatures of immune evasion and malignant progression in LSCC, suggesting that targeting STC1 may reprogram the immunosuppressive microenvironment and improve therapeutic outcomes.

PMID 42724726
阅读全文 →
PubMedChemMedChem2026-09-11

Phosphorylated Analogs of Paracetamol and Their Anti-Inflammatory Potential.

Cruz Osvaldo León de la OL, Gutiérrez-Rebolledo Gabriel Alfonso GA, Castro Carlos Zepactonal Gómez CZG, Juárez Ángel Daniel Campos ÁDC et al.

Paracetamol is a widely used analgesic and antipyretic agent; however, its use is limited by minimal anti-inflammatory activity and the risk of hepatotoxicity from prolonged oral use or in acute overdose. To address these limitations, four novel phosphorylated paracetamol analogs (2a-2d) were synthesized via a UV-radical methodology and evaluated through integrated in silico, in vitro, and in vivo for anti-inflammatory dermal approaches. Molecular docking suggested plausible binding interactions with COX-1 and COX-2 for all analogs. In vitro cytotoxicity assays in THP-1 cells showed that 2a and 2b did not affect cell viability at 100 μM over 24 h. In a TPA-induced acute ear edema model in CD1 male mice, 2a produced about 50% inhibition of edema at the lowest tested quantity (0.5 mg/ear), representing a fourfold potency advantage over indomethacin at the same amount, while 2b displayed significant anti-inflammatory and vasoregulatory activity at higher quantities. Computational ADME profiling indicated that all analogs satisfy Lipinski's drug-likeness criteria and exhibit low predicted hERG channel risk. These results support N-phosphorylation of 4-aminophenol as a viable strategy to improve the topical anti-inflammatory efficacy of paracetamol analogs.

PMID 42723329
阅读全文 →
PubMedJournal of thoracic disease2026-09-11

Clinical characteristics and prognostic markers of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease: a retrospective cohort study.

Zheng Yingshuo Y, Wu Yanjun Y, Zhu Weiwei W, Qi Haiyu H et al.

Anti-melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis-associated interstitial lung disease (DM-ILD) is a severe condition with high mortality, often manifesting as rapidly progressive ILD (RP-ILD). This study aimed to explore potential clinical and laboratory variables associated with mortality in patients with anti-MDA5 + DM-ILD in a small exploratory cohort. We retrospectively analyzed 25 patients with anti-MDA5-positive DM-ILD admitted to our institution. Baseline clinical characteristics, imaging features, treatments, and laboratory parameters (collected upon admission) were evaluated. Univariable and multivariable Firth's penalized likelihood logistic regression models were utilized to identify risk factors for mortality. The cohort included 6 males and 19 females (mean age 59.6±11.5 years). During the observation period, 16 patients survived and 9 died. Non-survivors exhibited significantly higher baseline levels of lactate dehydrogenase (LDH) (P=0.02) and D-dimer (P=0.03) compared to survivors. Univariable analysis indicated that both elevated LDH and D-dimer were associated with an increased risk of mortality. However, subsequent multivariable Firth regression analysis, adjusting for age, sex, and erythrocyte sedimentation rate (ESR), demonstrated that elevated baseline D-dimer was identified as a potential parameter associated with increased mortality [adjusted odds ratio (OR) =6.14, 95% confidence interval (CI): 1.69-135.73, P=0.003]. Baseline D-dimer elevation represents a potential prognostic indicator associated with poor survival in patients with anti-MDA5-positive DM-ILD. Assessing D-dimer levels upon admission provides crucial insights into the underlying severe vasculopathy, facilitating early risk stratification and the timely implementation of targeted therapies.

PMID 42724558
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多anti-tetanus immunoglobulin